Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
European Journal of Cancer2014Vol. 50(18), pp. 3145–3152
Citations Over TimeTop 10% of 2014 papers
Matthew I. Milowsky, Christian Dittrich, Ignacio Durán, Satinder Jagdev, Frederick Millard, Christopher J. Sweeney, Dean F. Bajorin, Linda Cerbone, David I. Quinn, Walter M. Stadler, Jonathan E. Rosenberg, Melissa Lochheed, Paramita Sen, Matthew Squires, Michael Shi, Cora N. Sternberg
Related Papers
- → In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia(2020)31 cited
- → Fibroblast growth factor receptor 3 and the human chondrodysplasias(1997)50 cited
- → Fibroblast Growth Factor Receptor 3 (FGFR3) Signaling in Achondroplasia(2016)
- → Fibroblast growth factor receptor (FGFR); fibroblast growth factor receptor 1 (FGFR1; CD331)(2011)